Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
165,547,872
-
Number of holders
-
123
-
Total 13F shares, excl. options
-
54,613,642
-
Shares change
-
+16,635,105
-
Total reported value, excl. options
-
$422,156,729
-
Value change
-
+$130,257,296
-
Put/Call ratio
-
280%
-
Number of buys
-
72
-
Number of sells
-
-53
-
Price
-
$7.73
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q1 2021
147 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q1 2021.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 123 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54,613,642 shares
of 165,547,872 outstanding shares and own 32.99% of the company stock.
Largest 10 shareholders include Point72 Asset Management, L.P. (6,335,000 shares), BVF INC/IL (5,576,471 shares), BlackRock Inc. (5,188,705 shares), VANGUARD GROUP INC (4,660,798 shares), RA CAPITAL MANAGEMENT, L.P. (3,500,000 shares), STATE STREET CORP (3,358,865 shares), VICTORY CAPITAL MANAGEMENT INC (2,768,882 shares), PERCEPTIVE ADVISORS LLC (2,153,974 shares), PRICE T ROWE ASSOCIATES INC /MD/ (1,696,266 shares), and RTW INVESTMENTS, LP (1,533,758 shares).
This table shows the top 123 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.